Syntara Ltd
ASX:SNT
Syntara Ltd
Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
Lead Drug Progress: Syntara’s key asset, amsulostat (formerly SNT-5505), received Fast Track designation from the FDA and an official generic name from the WHO, signaling meaningful advancement.
Strong Phase II Data: Interim results for amsulostat in myelofibrosis showed over 70% of patients achieving a 50% reduction in symptoms and more than 40% with notable spleen volume reduction, outperforming comparable drugs in development.
Upcoming Milestones: Final Phase II data for amsulostat will be released by the end of the current quarter, along with anticipated feedback from the FDA on Phase III trial design.
Partnership Interest: Management reported significant partnering interest from pharmaceutical companies, with the FDA’s upcoming guidance viewed as a key catalyst for potential deals.
Financials: The company ended the quarter with $15.1 million in cash, maintaining a monthly cash burn of about $1 million.
Pipeline Progress: Studies for new indications and programs—including MDS, skin scarring, and sleep disorders—are underway, with multiple clinical readouts expected in mid-2025 and early 2026.
Market Valuation: Management acknowledged a disconnect between operational progress and share price, attributing recent stock weakness to a large shareholder’s exit rather than company fundamentals.
